Amazon wants to sell you weight loss drugs the same way it sells you paper towels — fast, cheap, and with a few clicks.

The company launched a GLP-1 Management Program on Tuesday through its One Medical primary care arm, embedding obesity treatment into routine doctor visits and tying it directly to Amazon Pharmacy’s delivery network. The pitch: integrated primary care instead of standalone telehealth prescriptions, with transparent pricing and same-day delivery in nearly 3,000 US cities.

The pricing is competitive but not disruptive. Oral GLP-1 medications, including the newly approved Foundayo and Wegovy pills, start at $149 per month without insurance or as low as $25 with coverage, according to Amazon. Injectables like Wegovy and Eli Lilly’s Zepbound start at $299 cash-pay. Those numbers roughly match what’s already on the market from Hims & Hers, which offers Novo Nordisk-branded Wegovy and Ozempic at $149 through its own partnership.

Amazon’s edge is logistics, not price. Same-day delivery of prescription drugs, scaling to 4,500 cities by year-end 2026, plus 24/7 virtual prescription renewals starting at $29. The company is betting that convenience — and the credibility of integrated primary care — wins over patients currently using standalone telehealth platforms.

Wall Street noticed. Shares of Hims & Hers dropped as much as 10% before recovering to a 4% decline by midday, according to Motley Fool. Viking Therapeutics, Amgen, and Septerna also moved lower, per CNBC. The market signal is clear: Amazon’s entry into GLP-1 distribution is being treated as a credible threat to incumbents across the weight loss supply chain.

One Medical executives told Axios that patients have arrived from other providers “malnourished” or on improper doses — a pointed critique of the telehealth-first model that has driven much of the GLP-1 boom. Amazon is positioning its program as the responsible alternative: primary care clinicians adjusting doses based on full health profiles, managing related conditions like hypertension and diabetes alongside weight loss.

Walmart launched its own GLP-1 platform days earlier. The race between retailers to capture a multi-billion-dollar market is underway.

Sources